Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00760578 · ClinicalTrials.gov registry record · Phase 2
A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator
A Phase 2 study, sponsored by Metabolic Solutions Development Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT00760578: Completed Phase 2 study, sponsored by Metabolic Solutions Development Company.
NCT00760578 is a Phase 2 study that has completed, run by Metabolic Solutions Development Company. The registered enrollment target is 86 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00760578, a Phase 2 study, has completed, sponsored by Metabolic Solutions Development Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if MSDC-0160 is effective in the treatment of Type 2 diabetes.
Primary Outcome
Change from baseline of averaged postprandial glucose (mmol/L) in response to a Mixed-meal tolerance (MMT) test.
Interventions
- DRUG Placebo
- DRUG Pioglitazone
- DRUG MSDC-0160 90 mg
- DRUG MSDC-0160 220 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
What the finished NCT00760578 record still lists
NCT00760578 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00760578 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00760578 about?
NCT00760578 is a clinical study titled "A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator". The purpose of this study is to determine if MSDC-0160 is effective in the treatment of Type 2 diabetes.
What is the current status of trial NCT00760578?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2008-09. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00760578?
The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG), MSDC-0160 90 mg (DRUG), MSDC-0160 220 mg (DRUG).
Who is sponsoring clinical trial NCT00760578?
This trial is sponsored by Metabolic Solutions Development Company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00760578's enrollment target sits among peer trials
86 812th of 2000 higher than 1,181 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia